In the lab, multiple myeloma cells are killed by drugs similar to existing anti-diabetes drugs like Avandia or Actos, according to researchers at the University of Rochester School of Medicine and Dentistry, New York. Multiple myeloma is an uncommon cancer that arises in the bone marrow. Multiple myeloma cells express a receptor termed PPAR gamma, and so-called “glitazone” anti-diabetes drugs bind to this receptor.
